Coronary stent fracture and restenosis in the drug-eluting stent era: do we have clues of management?

Int J Cardiol. 2007 Sep 3;120(3):417-9. doi: 10.1016/j.ijcard.2006.08.019. Epub 2006 Nov 7.

Abstract

Despite the fact that the drug-eluting stents (DES) have markedly reduced neointimal proliferation, restenosis is still an open subject. Although DES fracture is very rare, it has been considered as one of the reasons for DES restenosis, however, the mechanism and proper management are not clearly elucidated yet. We describe two cases of sirolimus-eluting stent fracture combined with significant restenosis and suggest the possible revascularization strategies for successful management.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Coronary Restenosis / etiology*
  • Coronary Restenosis / therapy*
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Prosthesis Failure*
  • Sirolimus / administration & dosage
  • Stents / adverse effects*

Substances

  • Immunosuppressive Agents
  • Paclitaxel
  • Sirolimus